No headlines found.
Novanta Joins NVIDIA Halos AI Systems Inspection Lab
Business Wire (Mon, 16-Mar 4:40 PM ET)
Novanta Announces Financial Results for the Fourth Quarter and Full Year 2025
Business Wire (Mon, 23-Feb 4:45 PM ET)
Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, February 24, 2026
Business Wire (Thu, 22-Jan 11:00 AM ET)
Business Wire (Thu, 18-Dec 11:00 AM ET)
Novanta Inc supplies core technology solutions to medical, life science, and advanced industrial OEMs, leveraging proprietary expertise in precision medicine, precision manufacturing, robotics and automation, and advanced surgery. It has two segments: Automation Enabling Technologies and Medical Solutions. Automation Enabling Technologies, which generates the majority of revenue, provides laser beam steering and scanning solutions, laser sources, and robotic and precision motion technologies. The Medical Solutions segment provides medical-grade technologies, including medical insufflators, endoscopic pumps, and integrated operating room technologies. The company operates in the United States, Germany, and other markets, with revenue generated from the United States.
Novanta - Common Shares trades on the NASDAQ stock market under the symbol NOVT.
As of March 16, 2026, NOVT stock price climbed to $118.01 with 317,299 million shares trading.
NOVT has a beta of 1.99, meaning it tends to be more sensitive to market movements. NOVT has a correlation of 0.43 to the broad based SPY ETF.
NOVT has a market cap of $4.24 billion. This is considered a Mid Cap stock.
Last quarter Novanta - Common Shares reported $258 million in Revenue and $.91 earnings per share. This fell short of revenue expectation by $-320,002 and exceeded earnings estimates by $.03.
In the last 3 years, NOVT traded as high as $187.61 and as low as $98.27.
The top ETF exchange traded funds that NOVT belongs to (by Net Assets): VTI, IJH, VGT, VB, IWM.
NOVT has underperformed the market in the last year with a price return of -12.2% while the SPY ETF gained +22.6%. However, in the short term, NOVT had mixed performance relative to the market. It has outperformed in the last 3 months, returning -0.8% vs -1.6% return in SPY. But in the last 2 weeks, NOVT shares have been beat by the market, returning -12.2% compared to an SPY return of -2.5%.
NOVT support price is $112.22 and resistance is $121.30 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NOVT shares will trade within this expected range on the day.